What is the Return on Assets (ROA) of Immunitybio this year?
The Return on Assets (ROA) of Immunitybio is -1.16 undefined this year.
Immunitybio ROA 2024
Immunitybio ROA
-1.16
Ticker
IBRX
ISIN
US45256X1037
WKN
A2QQ2E
In 2024, Immunitybio's return on assets (ROA) was -1.16, a 0.58% increase from the -1.15 ROA in the previous year.
Immunitybio Aktienanalyse
What does Immunitybio do?
Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Immunitybio's Return on Assets (ROA)
Immunitybio's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Immunitybio's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Immunitybio's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Immunitybio’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Immunitybio Stock
What was the ROA of Immunitybio compared to the previous year?
The ROA of Immunitybio has increased by 0.58% compared to the previous year.
What consequences do high ROA have for investors of Immunitybio?
A high ROA is advantageous for investors of Immunitybio, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Immunitybio?
A low ROA can be unfavorable for investors of Immunitybio as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Immunitybio affect the company?
An increase in ROA of Immunitybio can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Immunitybio impact the company?
A reduction in the ROA of Immunitybio can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Immunitybio?
Some factors that can influence the ROA of Immunitybio include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Immunitybio important for investors?
The ROA of Immunitybio is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Immunitybio take to improve ROA?
To improve ROA, Immunitybio can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Immunitybio pay?
Over the past 12 months, Immunitybio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunitybio is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunitybio?
The current dividend yield of Immunitybio is .
When does Immunitybio pay dividends?
Immunitybio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunitybio?
Immunitybio paid dividends every year for the past 0 years.
What is the dividend of Immunitybio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunitybio located?
Immunitybio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunitybio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunitybio from 6/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/17/2024.
When did Immunitybio pay the last dividend?
The last dividend was paid out on 6/17/2024.
What was the dividend of Immunitybio in the year 2023?
In the year 2023, Immunitybio distributed 0 USD as dividends.
In which currency does Immunitybio pay out the dividend?
The dividends of Immunitybio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunitybio
Our stock analysis for Immunitybio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunitybio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
